Browse by Nurse Practitioner Items

Nurse practitioner PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED NURSE PRACTITIONERS

From 1 September 2010, nurse practitioners endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (authorised nurse practitioners) Information for nurse practitioners to become authorised PBS prescribers is available from the Department of Human Services.

The medicines listed for prescribing by authorised nurse practitioners from 1 November 2010 are identified by ‘NP’ in the PBS Schedule. Nurse practitioners must not write PBS prescriptions for other medicines.

PBS prescribing is limited by a nurse practitioner’s scope of practice, and state and territory prescribing rights. Prescribing of PBS medicines is also contingent on a prescriber being an authorised nurse practitioner and having collaborative arrangements in place, as required by amendments to the National Health Act 1953.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health regarding medicines for prescribing by authorised nurse practitioners.

Further to prescribing within collaborative arrangements, certain medicines also have additional conditions for prescribing by nurse practitioners, as recommended by the PBAC. These medicines are identified by the codes ‘CTO’ for continuation therapy only or ‘SCM’ for prescribing within a shared care model, as outlined below:

  • Continuing therapy only model

Where the patient’s treatment and prescribing of a medicine has been initiated by a medical practitioner, but prescribing is continued by a nurse practitioner. (This is similar to existing arrangements between specialists and medical practitioners for prescribing certain medicines.)

  • Shared care model

Where care is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed plan to manage the patient, in a patientcentred model of care. The details surrounding shared care arrangements will depend on the practitioners involved, patient needs and the healthcare context.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Nurse practitioner PBS prescriptions are identifiable by colour, and include the indicator ‘NP’ on personalised forms and a tick box on non-personalised (blank) forms.

Prescriptions must include the nurse practitioner’s PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms.  For authority required and authority required (streamlined) PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms.  Nurse practitioner PBS prescriptions may include repeats. 

Regulation 49 applies for nurse practitioner prescribing. A nurse practitioner can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from the Department of Human Services for each prescription. (Refer to Prescribing Medicines — Information for PBS prescribers and Supplying medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and territory requirements: Nurse practitioners may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the nurse practitioner’s responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

  • Legend
  • MPMedical Practitioner
  • MWMidwife
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MPNP 1566K LABETALOLlabetalol hydrochloride 100 mg tablet, 100 1 100 5
MPNP 1567L LABETALOLlabetalol hydrochloride 200 mg tablet, 100 1 100 5
MPNP 10293R LACOSAMIDElacosamide 50 mg tablet, 14 4 56 5
MPNP 9333F LACOSAMIDElacosamide 50 mg tablet, 14 1 14 1
MPNP 9336J LACOSAMIDElacosamide 150 mg tablet, 14 1 14 1
MPNP 9338L LACOSAMIDElacosamide 200 mg tablet, 56 1 56 5
MPNP 9335H LACOSAMIDElacosamide 100 mg tablet, 56 1 56 5
MPNP 9337K LACOSAMIDElacosamide 150 mg tablet, 56 1 56 5
MPNP 9334G LACOSAMIDElacosamide 100 mg tablet, 14 1 14 1
MPNP 2851C LAMOTRIGINElamotrigine 200 mg tablet, 56 1 56 5
MPNP 2850B LAMOTRIGINElamotrigine 100 mg tablet, 56 1 56 5
MPNP 8063J LAMOTRIGINElamotrigine 5 mg tablet, 56 1 56 5
MPNP 2849Y LAMOTRIGINElamotrigine 50 mg tablet, 56 1 56 5
MPNP 2848X LAMOTRIGINElamotrigine 25 mg tablet, 56 1 56 5
MPNP 9331D LANSOPRAZOLElansoprazole 15 mg orally disintegrating tablet, 28 1 28 5
MPNP 2240X LANSOPRAZOLElansoprazole 30 mg enteric capsule, 28 1 28 1
MPNP 2241Y LANSOPRAZOLElansoprazole 30 mg enteric capsule, 28 1 28 5
MPNP 9477T LANSOPRAZOLElansoprazole 30 mg orally disintegrating tablet, 28 1 28 1
MPNP 9478W LANSOPRAZOLElansoprazole 30 mg orally disintegrating tablet, 28 1 28 5
MPNP 8198L LANSOPRAZOLElansoprazole 15 mg enteric capsule, 30 1 30 5
MPNP 9403X LANTHANUMLANTHANUM Tablet, chewable, 500 mg (as carbonate hydrate), 90 1 90 5
MPNP 9404Y LANTHANUMLANTHANUM Tablet, chewable, 750 mg (as carbonate hydrate), 90 1 90 5
MPNP 9405B LANTHANUMLANTHANUM Tablet, chewable, 1000 mg (as carbonate hydrate), 90 1 90 5
MPNP 10628J LEDIPASVIR + SOFOSBUVIRledipasvir 90 mg + sofosbuvir 400 mg tablet, 28 1 28 2
MPNP 10668L LEDIPASVIR + SOFOSBUVIRledipasvir 90 mg + sofosbuvir 400 mg tablet, 28 1 28 1
MPNP 10670N LEDIPASVIR + SOFOSBUVIRledipasvir 90 mg + sofosbuvir 400 mg tablet, 28 1 28 5
MPNP 8534E LERCANIDIPINElercanidipine hydrochloride 10 mg tablet, 28 1 28 5
MPNP 8679T LERCANIDIPINElercanidipine hydrochloride 20 mg tablet, 28 1 28 5
MPNP 9144G LERCANIDIPINE + ENALAPRILlercanidipine hydrochloride 10 mg + enalapril maleate 10 mg tablet, 28 1 28 5
MPNP 9145H LERCANIDIPINE + ENALAPRILlercanidipine hydrochloride 10 mg + enalapril maleate 20 mg tablet, 28 1 28 5
MPNP 8245Y LETROZOLEletrozole 2.5 mg tablet, 30 1 30 5
MPNP 8654L LEVETIRACETAMlevetiracetam 250 mg tablet, 60 1 60 5
MPNP 9169N LEVETIRACETAMlevetiracetam 100 mg/mL oral liquid, 300 mL 1 1 5
MPNP 8655M LEVETIRACETAMlevetiracetam 500 mg tablet, 60 1 60 5
MPNP 8656N LEVETIRACETAMlevetiracetam 1 g tablet, 60 1 60 5
MPNP 2227F LEVODOPA + BENSERAZIDElevodopa 50 mg + benserazide 12.5 mg capsule, 100 1 100 5
MPNP 2228G LEVODOPA + BENSERAZIDElevodopa 200 mg + benserazide 50 mg tablet, 100 1 100 5
MPNP 2229H LEVODOPA + BENSERAZIDElevodopa 100 mg + benserazide 25 mg tablet, 100 1 100 5
MPNP 2225D LEVODOPA + BENSERAZIDElevodopa 100 mg + benserazide 25 mg capsule, 100 1 100 5
MPNP 2226E LEVODOPA + BENSERAZIDElevodopa 200 mg + benserazide 50 mg capsule, 100 1 100 5
MPNP 8219N LEVODOPA + BENSERAZIDElevodopa 100 mg + benserazide 25 mg dispersible tablet, 100 1 100 5
MPNP 8218M LEVODOPA + BENSERAZIDElevodopa 50 mg + benserazide 12.5 mg dispersible tablet, 100 1 100 5
MPNP 2231K LEVODOPA + BENSERAZIDElevodopa 100 mg + benserazide 25 mg modified release capsule, 100 1 100 5
MPNP 8970D LEVODOPA + CARBIDOPAlevodopa 20 mg/mL + carbidopa monohydrate 5 mg/mL intestinal gel, 7 x 100 mL 8 56 5
MPNP 1255C LEVODOPA + CARBIDOPAlevodopa 200 mg + carbidopa 50 mg modified release tablet, 100 1 100 5
MPNP 1242J LEVODOPA + CARBIDOPAlevodopa 100 mg + carbidopa 25 mg tablet, 100 1 100 5
MPNP 1245M LEVODOPA + CARBIDOPAlevodopa 250 mg + carbidopa 25 mg tablet, 100 1 100 5
MPNP 8797B LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 50 mg + carbidopa 12.5 mg + entacapone 200 mg tablet, 100 2 200 4
MPNP 8799D LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 150 mg + carbidopa 37.5 mg + entacapone 200 mg tablet, 100 2 200 4
MPNP 9345W LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 125 mg + carbidopa 31.25 mg + entacapone 200 mg tablet, 100 2 200 4
MPNP 9292C LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 200 mg + carbidopa 50 mg + entacapone 200 mg tablet, 100 2 200 4
MPNP 8798C LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 100 mg + carbidopa 25 mg + entacapone 200 mg tablet, 100 2 200 4
MPNP 9344T LEVODOPA + CARBIDOPA + ENTACAPONElevodopa 75 mg + carbidopa 18.75 mg + entacapone 200 mg tablet, 100 2 200 4
MPMWNP 2913H LEVONORGESTRELlevonorgestrel 30 microgram tablet, 112 tablets [4 x 28] 1 4 2
MPNP 8633J LEVONORGESTRELlevonorgestrel 52 mg intrauterine drug delivery system, 1 system 1 1 0
MPNP 1456P LEVONORGESTREL + ETHINYLESTRADIOLlevonorgestrel 125 microgram + ethinylestradiol 50 microgram tablet [21] (&) inert substance tablet [7], 4 x 28 1 4 2
MPNP 1392G LEVONORGESTREL + ETHINYLESTRADIOLethinylestradiol 30 microgram + levonorgestrel 50 microgram tablet [24] (&) ethinylestradiol 40 microgram + levonorgestrel 75 microgram tablet [20] (&) ethinylestradiol 30 microgram + levonorgestrel 125 microgram tablet [40] (&) inert substance tablet [28], 112 [4 x 28] 1 4 2
MPNP 1394J LEVONORGESTREL + ETHINYLESTRADIOLlevonorgestrel 150 microgram + ethinylestradiol 30 microgram tablet [21] (&) inert substance tablet [7], 4 x 28 1 4 2
MPNP 2416E LEVONORGESTREL + ETHINYLESTRADIOLlevonorgestrel 100 microgram + ethinylestradiol 20 microgram tablet [21] (&) inert substance tablet [7], 4 x 28 1 4 2
MPNP 2174K LEVOTHYROXINElevothyroxine sodium 50 microgram tablet, 200 1 200 1
MPNP 2173J LEVOTHYROXINElevothyroxine sodium 200 microgram tablet, 200 1 200 1
MPNP 9287T LEVOTHYROXINElevothyroxine sodium 75 microgram tablet, 200 1 200 1
MPNP 2175L LEVOTHYROXINElevothyroxine sodium 100 microgram tablet, 200 1 200 1
MPNP 2876J LIDOCAINE (LIGNOCAINE)lidocaine (lignocaine) hydrochloride 10% (500 mg/5 mL) injection, 10 x 5 mL ampoules 1 10 0
MPNP 10209H LIDOCAINE (LIGNOCAINE)lidocaine (lignocaine) hydrochloride monohydrate 1% (50 mg/5 mL) injection, 5 x 5 mL ampoules 1 5 0
MPNP 3387G LINAGLIPTINlinagliptin 5 mg tablet, 30 1 30 5
MPNP 10045Q LINAGLIPTIN + METFORMINlinagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60 1 60 5
MPNP 10038H LINAGLIPTIN + METFORMINlinagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60 1 60 5
MPNP 10044P LINAGLIPTIN + METFORMINlinagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60 1 60 5
MPMWNP 11380Y LINCOMYCINlincomycin 600 mg/2 mL injection, 5 x 2 mL ampoules 1 5 0
MPMWNP 2530E LINCOMYCINlincomycin 600 mg/2 mL injection, 5 x 2 mL vials 1 5 0
MPNP 2318B LIOTHYRONINEliothyronine sodium 20 microgram tablet, 100 1 100 2
MPNP 10474G LISDEXAMFETAMINElisdexamfetamine dimesilate 50 mg capsule, 30 1 30 5
MPNP 10486X LISDEXAMFETAMINElisdexamfetamine dimesilate 30 mg capsule, 30 1 30 5
MPNP 10492F LISDEXAMFETAMINElisdexamfetamine dimesilate 70 mg capsule, 30 1 30 5
MPNP 2457H LISINOPRILlisinopril 10 mg tablet, 30 1 30 5
MPNP 2456G LISINOPRILlisinopril 5 mg tablet, 30 1 30 5
MPNP 2458J LISINOPRILlisinopril 20 mg tablet, 30 1 30 5
MPNP 8290H LITHIUM CARBONATElithium carbonate 450 mg modified release tablet, 100 2 200 2
MPNP 3059B LITHIUM CARBONATElithium carbonate 250 mg tablet, 200 1 200 2
MPNP 11438B LONG CHAIN TRIGLYCERIDESlong chain triglycerides oral liquid, 15 x 225 mL bottles 2 2 5
MPNP 10889D LOPERAMIDEloperamide hydrochloride 2 mg capsule, 12 5 60 0
MPNP 1571Q LOPERAMIDEloperamide hydrochloride 2 mg capsule, 12 1 12 0
MPNP 5452Y LOSARTANlosartan potassium 25 mg tablet, 30 1 30 5
MPNP 8203R LOSARTANlosartan potassium 50 mg tablet, 30 2 60 5
MPNP 10526B LURASIDONElurasidone hydrochloride 40 mg tablet, 30 1 30 5
MPNP 10529E LURASIDONElurasidone hydrochloride 80 mg tablet, 30 1 30 5